SCHEMBL3767294

SCHEMBL3767294

CC(C)N1CCN(C(=O)CN2CCN(c3ccc(C#N)cc3)CC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
MAPT P10636 3/20 0.54
PKM P14618 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
POLB P06746 1/20 0.52
LMNA P02545 3/20 0.51
GAA P10253 1/20 0.51
GFER P55789 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PANK3 Q9H999 1/20 0.50
KDM4E B2RXH2 1/20 0.49
DPP4 P27487 1/20 0.47
HRH3 Q9Y5N1 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 1/20 0.45
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
MGLL Q99685 1/20 0.44
ELANE P08246 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3776083 0.90 ALDH1A1 (0.51) ALDH1A1MAPTPKMNPSR1POLB
SCHEMBL3776078 0.85 MAPT (0.59) ALDH1A1MAPTPKMNPSR1POLB
SCHEMBL25122016 0.84 PKM (0.60) ALDH1A1MAPTPKMNPSR1LMNA
SCHEMBL3769115 0.84 SMN1; SMN2 (0.71) ALDH1A1MAPTPKMNPSR1LMNA
SCHEMBL3768057 0.84 MAPT (0.58) ALDH1A1MAPTPKMNPSR1POLB
SCHEMBL26171578 0.84 PKM (0.60) ALDH1A1MAPTPKMNPSR1LMNA
SCHEMBL3771806 0.84 ALDH1A1 (0.58) ALDH1A1MAPTPKMNPSR1POLB
SCHEMBL3762814 0.84 MAPT (0.78) ALDH1A1MAPTPKMNPSR1LMNA
SCHEMBL3767673 0.83 ALDH1A1 (0.57) ALDH1A1MAPTPKMNPSR1LMNA
SCHEMBL23551688 0.82 ALDH1A1 (0.56) ALDH1A1MAPTPKMNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885MAPT 1475/4885PKM 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.